Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Lymphokines – e.g. – interferons – interlukins – etc.
Reexamination Certificate
2003-12-30
2009-08-25
Bunner, Bridget E. (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Lymphokines, e.g., interferons, interlukins, etc.
C424S085200, C424S192100, C514S012200
Reexamination Certificate
active
07579439
ABSTRACT:
The present invention is based, in part, on expression studies of IL-2 and IL-15 receptor subunits by cycling T cells in vivo. In one embodiment, the invention generally features novel combinations of IL-2 and IL-15 antagonists and methods of suppressing the immune response by administering these antagonists. In each case, suppression is achieved by administration of a first agent that targets an IL-15 molecule or an IL-15 receptor (IL-15R) and a second agent that targets an IL-2 molecule or an IL-2 receptor (IL-2R). More generally, the invention features novel combinations of agents that, when administered to a patient (or to a transplant ex vivo), reduce the number of antigen-reactive T cells. For example, the invention features compositions (e.g., pharamaceutically acceptable compositions) that include two or more agents, each of which promote T cell death. Alternatively, the composition can contain at least one agent that promotes T cell death and at least one agent that inhibits T cell proliferation. The agent that promotes T cell death can promote AICD (activation induced cell death), passive cell death, ADCC (antibody dependent cell-mediated cytotoxicity) or CDC (complement directed cytotoxicity).
REFERENCES:
patent: 5011684 (1991-04-01), Strom
patent: 5116964 (1992-05-01), Capon et al.
patent: 5552303 (1996-09-01), Grabstein et al.
patent: 5574138 (1996-11-01), Grabstein et al.
patent: 5707616 (1998-01-01), Grabstein et al.
patent: 5747024 (1998-05-01), Grabstein et al.
patent: 5892001 (1999-04-01), Grabstein et al.
patent: 198 23 351 (1998-05-01), None
patent: WO 88/07089 (1988-09-01), None
patent: WO 92/12726 (1992-08-01), None
patent: WO 94/06473 (1994-03-01), None
patent: WO 96/26274 (1996-08-01), None
patent: WO 97/41232 (1997-11-01), None
patent: WO 98/36768 (1998-08-01), None
Kim et al. The Journal of Immunlogy, 1998. vol. 160, pp. 5742-5748.
Strom et al. Transplantaion Proceedings, 1995, vol. 27, No. 5, Suppl 1, pp. 18-20.
Bernard et al, The Journal of Biological Chemistry, Jun. 2004, vol. 279, No. 23, pp. 24313-24322.
Wells, Biochemistry, 1990, vol. 29, pp. 509-8517.
Agostini, et al.CD8 T-Cell Infiltration in Extravascular Tissues of Patients with Human Immunodeficiency Virus Infection. Interleukin-15 Upmodulates Costimulatory Pathways Involved in the Antigen-Presenting Cells-T-Cell Interaction. Blood 93(4):1277-1286 (1999).
Anderson, et al.Functional Characterization of the Human Interleukin-15 Receptor α Chain and Close Linkage of IL15RA and IL2RA Genes. Journal of Biological Chemistry 270(5):29862-29869 (1995).
Bamford, et al.The interleukin(IL)2 receptor β chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc. Natl. Acad. Sci. USA 91:4940-4944 (1994).
Burger, et al.Imbalance between interstitial collagenase and tissue inhibitor of metalloproteinases 1 in synociocytes and fibroblasts upon direct contact with stimulated T LymphocytesArthritis & Rheumatism 41(10):1748-1759 (1998).
Burton, et al.A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc. Natl. Acad. Sci. USA 91:4935-4939 (1994).
Carson, et al.Interleukin(IL)I 5 Is a Novel Cytokine That Activates Human Natural Killer Cells via Components of the IL-2 Receptor. J. Exp. Med. 180:1395-1403 (1994).
Case, et al.Chimeric cytoxin IL2-PE40 delays and mitigates adjuvant-induced arthritis in rats. Proc. Natl. Acad. Sci. USA 86:287-291 (1989).
Chae, et al.Distribution of IL-15 Receptor α-Chains on Human Peripheral Blood Mononuclear Cells and Effect of Immunosuppressive Drugs on Receptor Expression. Journal of Immunology 157:2813-2819 (1996).
Chae, et al.Mutant IL-15 Protein lexerting Antagonistic Effects on IL-15 Triggered Cell Proliferation. JASN 7(9):1654 (1996).
Chang et al., “Blocking the common gamma chain of cytokine receptors induces T cell apoptosis and long term islet allograft survival,”J. Immunol. 164:1193-1199 (2000).
Courtenay, et al.Immunisation against heterologous type II collagen induces arthritis in mice. Nature 283(5748): 666-668 (1980).
Elliot, et al.Repeated therapy with monoclonal antibody to tumor necrosis factorα (cA2)in patients with rheumatoid arthritis. Lancet 344(8930):1125-1127 (1994).
Elliott, et al.Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factorα (cA2)versus placebo in rheumatoid arthritis. Lancet 344(8930):1105-1110 (1994).
Ferrari-Lacraz, et al.An Antagonist IL-15/Fc Protein Prevents Costimulation Blockade-Resistant Rejection. Journal of Immunology 167:3478-3485 (2001).
Giri, et al.Utilization of the β and γ chains of the IL-2 receptor by the novel cytokine IL-15. The EMBO Journal 13(12):2822-2830 (1994).
Giri, et al.Identification and cloning of a novel IL-15 binding protein that is structurally related to the α chain of the IL-2 receptor. The EMBO Journal 14(15):3654-3663 (1995).
Giri, et al.IL-15, a novel T cell growth factor that shares activities and receptor components with IL-2. Journal of Leukocyte Biology 57(5):763-766 (1995).
Grabstein, et al.Cloning of a T Cell Growth Factor That Interacts with the β Chain of the Interleukin-2 Receptor. Science 264:965-968 (1994).
Hatakeyama, et al.A Restricted Cytoplasmic Region of IL-2 Receptor β Chain Is Essential for Growth Signal Transduction but Not for Ligand Binding and Internalization. Cell 59:837-845 (1989).
Kim, et al.Targeting the IL-15 Receptor with an Antagonist IL-15 Mutant/Fcγ2a Protein Blocks Delayed-Type Hypersensitivity. Journal of Immunology 160:5742-5748 (1998).
Kim, et al.Targeting the IL-15 Receptor with an Antagonist IL-15/Fcγ2a Protein BlocksDTH and Enhances the Acceptance of Islet Allografts. 17thASTP (Physicist) Annual Meeting, Chicago, IL May 9-13, 1998 (p. 713).
Kim, et al.Immunoglobulin-Cytokine Fusion Molecules: The New Generation of Immunomodulating Agents. Transplantation Proceedings 30:4031-4036 (1998).
Li, et al.Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nature Medicine 5(11):1298-1302 (1999).
Li, et al.Induction of Allograft Tolerance in the Absence of Fas-Mediated Apoptosis. Journal of Immunology 163:2500-2507 (1999).
Lin, et al.The Role of Shared Receptor Motifs and Common Stat Proteins in the Generation of Cytokine Pleiotropy and Redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity, 2:331-339 (Apr. 1995).
Maslinski, et al.Intoxication of high affinity IL-2 receptor positive thymocytes blocks early stages of T cell maturation. International Immunology 4(4):509-517 (1992).
Maslinski, et al.Interleukin-2(IL-2)Induces Tyrosine Kinase-dependant Translocation of Active Raf-1 from the IL-2 Receptor into the Cytosol. Journal of Biological Chemistry 267(22):15281-15284 (1992).
Moreland, et al.Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor(p75)-Fc Fusion Protein. N. Engl. J. Med 337(3):141-147 (1997).
Morrison, et al.Structural Determinants of Human IgG Function. The Immunologist 2(4):119-124 (1994).
Pettit, et al.Polyethylene Glycol Conjugation to Lysine Residues of Recombinant IL-15 Geenrates a Specific IL-15 Antagonist. Proceed. Intern. Symp. Control. Rel. Bioact. Mater. 22:496-497 (1995).
Pettit, et al.Structural-Function Studies of Interleukin 15 using Site-specific Mutagenesis, Polyethylene Glycol Conjugation, and Homology Modeling. The Journal of Biologial Chemistry 272(4):2312-2318 (1997).
Remillard, et al.Interleukin-2 Receptor Regulates Activation of Phosphatidylinositol 3- Kinase. Journal of Biological Chemistry 266(22):14167-14170 (1991).
Stevens, et al.Interleukin-15 signal, T84 colonic epithelial cells in the absence of the interleukin-2 receptor β-chain. Am. J. Physiol. 272:G1-G8 (1997).
Stunkel, et al.Monitoring of interleukin-2 receptor(IL-2R)
Li Xian Chang
Strom Terry B.
Zheng Xin Xiao
Beth Israel Deaconess Medical Center Inc.
Bunner Bridget E.
Fish & Richardson P.C.
Hamud Fozia M
LandOfFree
Modulation of IL-2- and IL-15-mediated T cell responses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of IL-2- and IL-15-mediated T cell responses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of IL-2- and IL-15-mediated T cell responses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4064436